BlackRock’s FibroBiologics FBLG Stock Holding History

BlackRock’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3K	Sell	18,238 -6,409	-26%	-$7.44K	﹤0.01%	5379
2026 Q1	$32.5K	Buy	24,647 +527	+2%	+$3.13K	﹤0.01%	5216
2025 Q4	$108K	Buy	24,120 +2,131	+10%	+$15K	﹤0.01%	4886
2025 Q3	$240K	Sell	21,989 -15,556	-41%	-$186K	﹤0.01%	4641
2025 Q2	$467K	Sell	37,545 -50,737	-57%	-$915K	﹤0.01%	4460
2025 Q1	$1.59M	Sell	88,282 -1,028	-1%	-$29.4K	﹤0.01%	4062
2024 Q4	$3.57M	Buy	89,310 +1,480	+2%	+$79.4K	﹤0.01%	3856
2024 Q3	$5.43M	Buy	87,830 +41,882	+91%	+$2.78M	﹤0.01%	3664
2024 Q2	$4.59M	Buy	45,948 +45,288	+6,862%	+$8.64M	﹤0.01%	3715
2024 Q1	$143K	Buy	+660	New	+$159K	﹤0.01%	4658

Other funds holding FBLG

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's FBLG Position: Q2 2026 in Review

BlackRock reduced its FibroBiologics (FBLG) stake by 26% in Q2 2026, selling an estimated $7.44K and leaving 18,238 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5379.

BlackRock first reported a position in FBLG in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.43M in Q3 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

BlackRock held 18,238 shares of FibroBiologics worth $17.3K as of Q2 2026.
BlackRock sold 6,409 FibroBiologics shares in Q2 2026, an estimated $7.44K.
FibroBiologics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5379 holding.
BlackRock first reported a position in FibroBiologics in Q1 2024 and has held it in 10 quarters since.
BlackRock's FibroBiologics position peaked at $5.43M in Q3 2024.
16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.